title: [Intraoperative intraperitoneal chemoperfusion treatment with cisplatin and dioxadet on a model of peritoneal carcinomatosis in ovarian cancer: safety and efficacy evaluation].
abstract: A comparative study of safety and efficacy of normothermic and hyperthermic intraperitoneal chemoperfusion (IPEC and HIPEC) with cisplatin and dioxadet was carried out in 143 female Wistar rats. Ovarian cancer was inoculated intraperitoneally (i.p.). In 48 hours after ovarian cancer inoculation the drugs were administered i.p. or IPEC and HIPEC with the drugs were performed using maximum tolerated doses (MTD). Content of cisplatin was determined in the perfusate and blood plasma during HIPEC with the drug. The leukocyte count was measured using veterinary hematologic analyzer in peripheral blood of rats at different time points after HIPEC with dioxadet. Efficacy of the treatment was estimated in increase in median survival time (MST). During HIPEC cisplatin was accumulated in the abdominal cavity in a considerable amount with minimal systemic absorption. HIPEC with dioxadet didn't significantly affect the leukocyte count in peripheral blood while i.p. administration of dioxadet suppressed leukopoiesis. MST of rats after IPEC with cisplatin was 37.5 days which was significantly higher compared to MST after i.p. administration of cisplatin (19.5 days, p = 0.037). HIPEC with dioxadet was the most effective regimen of treatment with MST of rats reaching 49 days which was significantly higher compared to MST after HIPEC with cisplatin (25.5 days, p = 0.002).
authors.forename: V G
authors.initials: VG
authors.lastname: Bespalov
authors.forename: G S
authors.initials: GS
authors.lastname: Kireeva
authors.forename: O A
authors.initials: OA
authors.lastname: Belyaeva
authors.forename: K Yu
authors.initials: KY
authors.lastname: Senchik
authors.forename: A N
authors.initials: AN
authors.lastname: Stukov
authors.forename: G I
authors.initials: GI
authors.lastname: Gafton
authors.forename: L A
authors.initials: LA
authors.lastname: Soloviev
authors.forename: M V
authors.initials: MV
authors.lastname: Vasilchenko
authors.forename: K D
authors.initials: KD
authors.lastname: Guseinov
authors.forename: V V
authors.initials: VV
authors.lastname: Alexeev
authors.forename: A M
authors.initials: AM
authors.lastname: Belyaev
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D010478:Chemotherapy, Cancer, Regional Perfusion; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D006979:Hyperthermia, Induced; D007432:Intraoperative Period; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery / Q000628:therapy*; D010529:Peritoneal Cavity; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000556:secondary / Q000601:surgery / Q000628:therapy*; D051381:Rats; D017208:Rats, Wistar; D016019:Survival Analysis; D014227:Triazines / Q000008:administration & dosage
chemical_list: D014227:Triazines; C040269:dioxadet; D002945:Cisplatin